Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Julvez J, Paus T, Bellinger D, Eskenazi B, Tiemeier H, Pearce N, Ritz B, White T, Ramchandani P, Gispert JD, Desrivieres S, Brouwer R, Boucher O, Alemany S, Lopez-Vicente M, Suades-Gonzalez E, Forns J, Grandjean P, Sunyer J. Environment and brain development: challenges in the global context. Neuroepidemiology. 2016;46(2):79-82. doi: 10.1159/000442256
Forns J, Aranbarri A, Grellier J, Julvez J, Vrijheid M, Sunyer J. A conceptual framework in the study of neuropsychological development in epidemiological studies. Neuroepidemiology. 2012 Jun;38(4):203-8. doi: 10.1159/000337169
Fischer T, Johnsen SP, Pedersen L, Gaist D, Sorensen HT, Rothman KJ. Seasonal variation in hospitalization and case fatality of subarachnoid hemorrhage - A nationwide Danish study on 9,367 patients. Neuroepidemiology. 2005 Jan 1;24(1-2):32-7.